Citations (65)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (28)
Mingjun Zhao, Bin Qin, Yage Mao, Yang Zhang, Ruisheng Zhao, Aiqin Wang, Hailing Wang, Jianting Zhao & Changhong Wang. (2023) Paliperidone Palmitate versus Risperidone Long-Acting Injectable in Patients with Schizophrenia: A Meta-Analysis of Efficacy and Safety. Neuropsychiatric Disease and Treatment 19, pages 749-757.
Read now
Read now
Mingjun Zhao, Bin Qin, Yage Mao, Hailing Wang, Aiqin Wang & Chuansheng Wang. (2022) Efficacy and Safety of Low-Dose Brexpiprazole for Acute Schizophrenia: Meta-Analysis of Randomized Placebo-Controlled Trials. Neuropsychiatric Disease and Treatment 18, pages 1705-1713.
Read now
Read now
Leslie Citrome, Joseph P McEvoy, Mark S Todtenkopf, David McDonnell & Peter J Weiden. (2019) A commentary on the efficacy of olanzapine for the treatment of schizophrenia: the past, present, and future. Neuropsychiatric Disease and Treatment 15, pages 2559-2569.
Read now
Read now
Leslie Citrome. (2018) Cariprazine for acute and maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy. Neuropsychiatric Disease and Treatment 14, pages 2563-2577.
Read now
Read now
Myrlene S Aigbogun, Sizhu Liu, Siddhesh A Kamat, Christophe Sapin, Amy M Duhig & Leslie Citrome. (2018) Relapse prevention: a cost-effectiveness analysis of brexpiprazole treatment in adult patients with schizophrenia in the USA. ClinicoEconomics and Outcomes Research 10, pages 443-456.
Read now
Read now
Leslie Citrome. (2018) Tardive dyskinesia: placing vesicular monoamine transporter type 2 (VMAT2) inhibitors into clinical perspective. Expert Review of Neurotherapeutics 18:4, pages 323-332.
Read now
Read now
Leslie Citrome. (2017) Long-acting injectable antipsychotics update: lengthening the dosing interval and expanding the diagnostic indications. Expert Review of Neurotherapeutics 17:10, pages 1029-1043.
Read now
Read now
Leslie Citrome. (2016) Schizophrenia relapse, patient considerations, and potential role of lurasidone. Patient Preference and Adherence 10, pages 1529-1537.
Read now
Read now
Eva G Katz, Brett Hauber, Srihari Gopal, Angie Fairchild, Amy Pugh, Rachel B Weinstein & Bennett S Levitan. (2016) Physician and patient benefit–risk preferences from two randomized long-acting injectable antipsychotic trials. Patient Preference and Adherence 10, pages 2127-2139.
Read now
Read now
Leslie Citrome. (2016) Aripiprazole long-acting injectable formulations for schizophrenia: aripiprazole monohydrate and aripiprazole lauroxil. Expert Review of Clinical Pharmacology 9:2, pages 169-186.
Read now
Read now
Leslie Citrome, Anna Eramo, Clement Francois, Ruth Duffy, Susan N Legacy, Steve J Offord, Holly B Krasa, Stephen S Johnston, Alice Guiraud-Diawara, Siddhesh A Kamat & Patricia Rohman. (2015) Lack of tolerable treatment options for patients with schizophrenia. Neuropsychiatric Disease and Treatment 11, pages 3095-3104.
Read now
Read now
Leslie Citrome, Tine Bryan Stensbøl & Kenji Maeda. (2015) The preclinical profile of brexpiprazole: what is its clinical relevance for the treatment of psychiatric disorders?. Expert Review of Neurotherapeutics 15:10, pages 1219-1229.
Read now
Read now
Leslie Citrome, Siddhesh A. Kamat, Christophe Sapin, Ross A. Baker, Anna Eramo, Jesse Ortendahl, Benjamin Gutierrez, Karina Hansen & Tanya G. K. Bentley. (2014) Cost-effectiveness of aripiprazole once-monthly compared with paliperidone palmitate once-monthly injectable for the treatment of schizophrenia in the United States. Journal of Medical Economics 17:8, pages 567-576.
Read now
Read now
Leslie Citrome. (2014)
Asenapine review, part I: chemistry, receptor affinity profile, pharmacokinetics and metabolism. Expert Opinion on Drug Metabolism & Toxicology 10:6, pages 893-903.
Read now
Read now
Leslie Citrome. (2014)
Asenapine review, part II: clinical efficacy, safety and tolerability. Expert Opinion on Drug Safety 13:6, pages 803-830.
Read now
Read now
Navin V Dargani & Anil K Malhotra. (2014) Safety profile of iloperidone in the treatment of schizophrenia. Expert Opinion on Drug Safety 13:2, pages 241-246.
Read now
Read now
Victor Voicu, Andrei Medvedovici, Aurelian Emil Ranetti & Flavian Ştefan Rădulescu. (2013)
Drug-induced hypo- and hyperprolactinemia: mechanisms, clinical and therapeutic consequences
. Expert Opinion on Drug Metabolism & Toxicology 9:8, pages 955-968.
Read now
Read now
Leslie Citrome. (2013) New second-generation long-acting injectable antipsychotics for the treatment of schizophrenia. Expert Review of Neurotherapeutics 13:7, pages 767-783.
Read now
Read now
Leslie Citrome. (2013)
Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability. Expert Opinion on Drug Metabolism & Toxicology 9:2, pages 193-206.
Read now
Read now
William V Bobo. (2013) Asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults. Expert Review of Clinical Pharmacology 6:1, pages 61-91.
Read now
Read now
Leslie Citrome. (2012) A systematic review of meta-analyses of the efficacy of oral atypical antipsychotics for the treatment of adult patients with schizophrenia. Expert Opinion on Pharmacotherapy 13:11, pages 1545-1573.
Read now
Read now
Leslie Citrome & Henry A Nasrallah. (2012) On-label on the table: what the package insert informs us about the tolerability profile of oral atypical antipsychotics, and what it does not. Expert Opinion on Pharmacotherapy 13:11, pages 1599-1613.
Read now
Read now
Leslie Citrome. (2012) Oral paliperidone extended-release: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability. Expert Opinion on Drug Metabolism & Toxicology 8:7, pages 873-888.
Read now
Read now
Joshua T Kantrowitz & Leslie Citrome. (2012) Lurasidone for schizophrenia: what’s different?. Expert Review of Neurotherapeutics 12:3, pages 265-273.
Read now
Read now
Leslie Citrome. (2011) Role of sublingual asenapine in treatment of schizophrenia. Neuropsychiatric Disease and Treatment 7, pages 325-339.
Read now
Read now
Leslie Citrome. (2011) Drug safety evaluation of ziprasidone. Expert Opinion on Drug Safety 10:3, pages 437-448.
Read now
Read now
Leslie Citrome. (2011) Iloperidone, Asenapine, and Lurasidone: A Brief Overview of 3 New Second-Generation Antipsychotics. Postgraduate Medicine 123:2, pages 153-162.
Read now
Read now
Leslie Citrome. (2010) Iloperidone: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability, regulatory affairs, and an opinion. Expert Opinion on Drug Metabolism & Toxicology 6:12, pages 1551-1564.
Read now
Read now
Articles from other publishers (37)
Marco De Pieri, Marco Ferrari, Franca Marino, Rafael Traber, Emilio Bolla & Marco Cosentino. (2023) Functional single nucleotide polymorphisms in dopaminergic receptors D2 predict clinical response to Cariprazine. Frontiers in Pharmacology 14.
Crossref
Crossref
Ashish Patel, Arya Patel, Darshini Patel, Krina Patel & Tushar Bambharoliya. (2023) Mini Review on Cariprazine: A Promising Antipsychotic Agent. CNS & Neurological Disorders - Drug Targets 22:2, pages 226-236.
Crossref
Crossref
Zhao-Han Huang, Yuan Fang, Qi Yu & Tong Wang. (2023) Efficacy and duration of electro-Acupuncture combined with conventional antipsychotics for schizophrenia: A meta-analysis. World Journal of Traditional Chinese Medicine 0:0, pages 0.
Crossref
Crossref
Lian Beijers, Hanna M. van Loo, Jan-Willem Romeijn, Femke Lamers, Robert A. Schoevers & Klaas J. Wardenaar. (2020) Investigating data-driven biological subtypes of psychiatric disorders using specification-curve analysis. Psychological Medicine 52:6, pages 1089-1100.
Crossref
Crossref
Georgi Panov Panov. (2022) Early Markers in Resistant Schizophrenia: Effect of the First Antipsychotic Drug. Diagnostics 12:4, pages 803.
Crossref
Crossref
Siddhanath D. Bhosle, Shivanand V. Itage, Balraju Gangapuram, Gyanchander Eppa, Rajesh S. Bhosale & Jhillu Singh Yadav. (2022) Review of Synthetic Approaches toward the Synthesis of Cariprazine, an Antipsychotic Drug. Organic Process Research & Development 26:3, pages 493-507.
Crossref
Crossref
Leslie Citrome. (2021) Long-acting injectable antipsychotics: what, when, and how. CNS Spectrums 26:2, pages 118-129.
Crossref
Crossref
Fang Yan, Yang Yang, Qingzhi Huang, Yun Chen, Peiqi Jia, Wendong Chen & Xin Ma. (2018) Cost-effectiveness of a free drug program for schizophrenia in Beijing, China. International Journal of Social Psychiatry 65:1, pages 28-37.
Crossref
Crossref
Kristen M. Ward & Leslie Citrome. (2018) Antipsychotic-Related Movement Disorders: Drug-Induced Parkinsonism vs. Tardive Dyskinesia—Key Differences in Pathophysiology and Clinical Management. Neurology and Therapy 7:2, pages 233-248.
Crossref
Crossref
Ming-jun Zhao, Bin Qin, Jin-bao Wang, Yan-ping Zhang, Jian-ting Zhao, Ya-ge Mao, Xiang-yang Zhang & Rui-ling Zhang. (2018) Efficacy and Acceptability of Cariprazine in Acute Exacerbation of Schizophrenia. Journal of Clinical Psychopharmacology 38:1, pages 55-59.
Crossref
Crossref
Pierre-Michel Llorca, Christophe Lançon, Ann Hartry, T. Michelle Brown, Dana B. DiBenedetti, Siddhesh A. Kamat & Clément François. (2017) Assessing the burden of treatment-emergent adverse events associated with atypical antipsychotic medications. BMC Psychiatry 17:1.
Crossref
Crossref
Stephen R. Marder, Mika Juhani Hakala, Mette Krog Josiassen, Peter Zhang, John Ouyang, Emmanuelle Weiller, Catherine Weiss & Mary Hobart. (2016) Brexpiprazole in patients with schizophrenia: overview of short- and long-term phase 3 controlled studies. Acta Neuropsychiatrica 29:5, pages 278-290.
Crossref
Crossref
William M. Greenberg & Leslie Citrome. (2016) Pharmacokinetics and Pharmacodynamics of Lurasidone Hydrochloride, a Second-Generation Antipsychotic: A Systematic Review of the Published Literature. Clinical Pharmacokinetics 56:5, pages 493-503.
Crossref
Crossref
Leslie Citrome. (2017) Emerging pharmacological therapies in schizophrenia: what’s new, what’s different, what’s next?. CNS Spectrums 21:S1, pages 1-12.
Crossref
Crossref
Leslie Citrome, Ai Ota, Kazuhiro Nagamizu, Pamela Perry, Emmanuelle Weiller & Ross A. Baker. (2016) The effect of brexpiprazole (OPC-34712) and aripiprazole in adult patients with acute schizophrenia. International Clinical Psychopharmacology 31:4, pages 192-201.
Crossref
Crossref
John M. Kane, Aleksandar Skuban, Mary Hobart, John Ouyang, Emmanuelle Weiller, Catherine Weiss & Christoph U. Correll. (2016) Overview of short- and long-term tolerability and safety of brexpiprazole in patients with schizophrenia. Schizophrenia Research 174:1-3, pages 93-98.
Crossref
Crossref
Joseph McEvoy & Leslie Citrome. (2016) Brexpiprazole for the Treatment of Schizophrenia: A Review of this Novel Serotonin-Dopamine Activity Modulator. Clinical Schizophrenia & Related Psychoses 9:4, pages 177-186.
Crossref
Crossref
L. Citrome. (2015) Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic - what is the number needed to treat, number needed to harm and likelihood to be hel. International Journal of Clinical Practice 69:9, pages 978-997.
Crossref
Crossref
Leslie Citrome, Peter J. Weiden, Gus Alva, Ira D. Glick, Richard Jackson, Greg Mattingly, Farid Kianifard, Xiangyi Meng & Adam Winseck. (2015) Switching to Iloperidone. Clinical Schizophrenia & Related Psychoses 8:4, pages 183-195.
Crossref
Crossref
. (2014) Review: 15 antipsychotic drugs are more effective than placebo for the treatment of schizophrenia, but vary in their tolerability. Evidence Based Mental Health 17:1, pages 9-9.
Crossref
Crossref
Leslie Citrome. (2013) A Review of the Pharmacology, Efficacy and Tolerability of Recently Approved and Upcoming Oral Antipsychotics: An Evidence-Based Medicine Approach. CNS Drugs 27:11, pages 879-911.
Crossref
Crossref
Leslie Citrome. (2013) Cariprazine in Schizophrenia: Clinical Efficacy, Tolerability, and Place in Therapy. Advances in Therapy 30:2, pages 114-126.
Crossref
Crossref
Leslie CitromeLeslie Citrome. 2013. Handbook of Treatment-resistant Schizophrenia. Handbook of Treatment-resistant Schizophrenia
37
56
.
Leslie Citrome. (2012) Oral Antipsychotic Update: A Brief Review of New and Investigational Agents for the Treatment of Schizophrenia. CNS Spectrums 17:s1, pages 1-9.
Crossref
Crossref
Leslie Citrome. (2012) Lurasidone in Schizophrenia: New Information About Dosage and Place in Therapy. Advances in Therapy 29:10, pages 815-825.
Crossref
Crossref
Roberto Cavallaro, Marta Bosia, Carmelo Guglielmino & Enrico Smeraldi. (2012) 9-OH risperidone response in risperidone poor responders: An open study of drug response concordance. Neurology, Psychiatry and Brain Research 18:3, pages 109-113.
Crossref
Crossref
Tanuja Bordia, J. Michael McIntosh & Maryka Quik. (2012) Nicotine Reduces Antipsychotic-Induced Orofacial Dyskinesia in Rats. Journal of Pharmacology and Experimental Therapeutics 340:3, pages 612-619.
Crossref
Crossref
Jessica M. Henry & Matthew A. Fuller. (2011) Asenapine. Journal of Pharmacy Practice 24:5, pages 447-451.
Crossref
Crossref
Leslie Citrome. (2011) Treatment-refractory schizophrenia: what is it and what has been done about it?. Neuropsychiatry 1:4, pages 325-347.
Crossref
Crossref
L. Citrome. (2011) Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic. International Journal of Clinical Practice 65:2, pages 189-210.
Crossref
Crossref
Leslie Citrome. (2011) Lurasidone for Schizophrenia: A Brief Review of a New Second-Generation Antipsychotic. Clinical Schizophrenia & Related Psychoses 4:4, pages 251-257.
Crossref
Crossref
Oliver Freudenreich. (2014) Targeted Care Plans for Schizophrenia. CNS Spectrums 15:S8, pages 6-9.
Crossref
Crossref
L. Citrome. (2010) Iloperidone redux: a dissection of the Drug Approval Package for this newly commercialised second-generation antipsychotic. International Journal of Clinical Practice 64:6, pages 707-718.
Crossref
Crossref
John M. Kane, Michael Cohen, Jun Zhao, Larry Alphs & John Panagides. (2010) Efficacy and Safety of Asenapine in a Placebo- and Haloperidol-Controlled Trial in Patients With Acute Exacerbation of Schizophrenia. Journal of Clinical Psychopharmacology 30:2, pages 106-115.
Crossref
Crossref
. (2010) Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety 19:3, pages i-xiii.
Crossref
Crossref
L. Citrome. (2009) Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic. International Journal of Clinical Practice 63:12, pages 1762-1784.
Crossref
Crossref
Leslie Citrome. (2009) Using oral ziprasidone effectively: the food effect and dose-response. Advances in Therapy 26:8, pages 739-748.
Crossref
Crossref